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1. Introduction 
Adequate hemostasis is a prerequisite in neurosurgery, to prevent dramatic postoperative 
bleedings and their consequences. Different sorts of local hemostatic agents have been 
developed, with a variable efficacy. Some of them have been used for years, none being 
perfect. 
The residual presence of these agents may behave as foreign bodies, and induce 
inflammation, infection, and even delayed bone growth. 
Safety is an other concern since most of modern agents contain more or less human and 
animal components. 
We are going to review the history of those agents, their different categories, compare them 
and try to establish some guidelines when using them, with their different indications. 
2. Hemostasis (basis) 
Hemostasis comes from the coordinated activation of platelets and plasma clotting factors to 
form a platelet fibrin clot. Two processes, primary and secondary hemostasis activation of 
the clotting cascade id done by collagen for the intrinsic pathway, and the extrinsic pathway 
is activated by the release of tissue factors from the damaged zone. The two converge ento 
the common pathway which begins with the conversion of Factor X to Xa, the conversion of 
prothrombin to thrombin, which is integral in clot stabilization via fibrin. This common 
pathway is facilitated by Factor V (Hawiger 1987).  
3. History 
From the beginning of the neurosurgical practice, local hemostatic agents have proved to be 
very useful completing the more classical use of the electrocoagulation whatever its type, 
mono or bipolar or sometimes laser. 
3.1 First attempts  
3.1.1 Auto or hetero-muscle application  
Until the early 1950, neurosurgeons used as topical hemostatic agents fresh chicken breast 
which was delivered to the operative theatre just before the beginning of the operation. 
Electrocoagulation device was not very good, and they often had to apply the chicken flesh 
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on the brain during ten minutes while washing the field with warm serum, and removed it 
before closing the dura. 
Fresh muscle harvested from the temporal site or the thigh is still commonly used for 
extradural dural hemostasis and may be left in situ. 
At the same times, bone wax was used and is still used for bone hemostasis (Grant 2007). 
Bone wax was created by Sir Victor Haden Horsley (1857-1916) from beewax in 1892. Since 
this period different components were added to wax, but the common name remained 
“Horsley wax”. 
3.2 Hydrogen peroxide 
It has been used for decades as a hemostatic agent and is believed to establish hemostasis 
through its vasoconstrictive properties, and is also credited to create a disruption of the 
blood-barrier and an aggregation of the platelets and neutrophils leading to thrombus 
formation. The free diffusion of H2O2 through the vessel walls and its conversion to water 
and 02 leads to intra-luminal bubbles, micro-embolisms and vessels obstruction.  
3.3 Modern evolution 
Multiple local hemostatic agents now exist (Abaut & Basle 2003, Grant 2007) 
3.3.1 Fibrin sealants 
The better understanding of hemostasis mechanisms brought new perspectives for the 
conception of other local agents. The first discussion for topical agents is due to Bergen who 
emphasized the role of fibrin in hemostasis. Secundary, this will move to the preparation of 
fibrin sealants, the first combination of bovine thrombin with human plasma for topical use. 
In 1938, purified thrombin became available, with obtention of new fibrin sealants used in 
1940, as reported in the literature, even for nerve repair. In 1944, their use was reported to 
optimize skin-grafts survival and adhesion of skin grafts, in severe burn injury during the 
war by Cronkite. Richard Upjohn Light 1945 reviews the different existing helps to improve 
hemostasis in neurosurgery, and Fincher 1946 reports the uses of gelatin foam . 
But the technics used in those times only led to preparations being the potential source of 
transmission of viral hepatitis. So bovine thrombin was substituted for human thrombin to 
minimize the risk of viral transmission. But some patients developed coagulopathies due to 
the use of bovine thrombin related to immune-mediated production of thrombin and 
factorV inhibitors. 
All these difficulties led to abandon the fibrin sealants for years. 
In the late 1960, isolation and concentration of clotting factors from human plasma became 
possible, and in 1972, Matras produced the first item of modern fibrin sealants. The first 
commercially fibrin sealant was approved in Europe in 1982, and Later in USA in 1990. 
In 1998, Tisseel and Hemascel sealants were approved by FDA, and the firs sealant with 
entirely human components called Crosseals was made in 1993. Surgical use widely spread 
in nearly all specialities.  
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3.3.2 Gelatin hemostatic agents  
They were introduced in 1940 such as Gelfoam and Surgifoam. 
Gelfoam is a purified pork skin gelatine with hemostatic properties which may come from 
its physical features, and not from an effect on the clotting cascade. It may be used with 
saturated thrombin. 
They exist as sponges and have a capacity to expand up to 200% in vivo, which may be a 
negative property in some deep fields specially in neurosurgery. 
Floseal combines human derivated thrombin with bovine derivated gelatin matrix 
granules which are mixed at the time of use, and also exists as a liquid device minimizing 
the expansion property, allowing its application in minimal invasive surgery and 
neurosurgery. 
3.3.3 Cyanoacrylate adhesives  
They were developed by Dr H Coover in 1942. It consists cyanoacrylate monomers which 
polymerize in long chains in the presence of hydroxyl ions.  
3.3.4 Oxyfied regenerated glucose 
Is a plant –based topical hemostatic introduced in 1960. It is made by regenerating a pure 
plant-derived cellulose secondary knitted and oxidized. It acts as a scaffold for clot 
formation. On post-operative imaging, it may mimic an abcess or some residual tumor. 
3.3.5 Microfibrillar collagen 
This substance (Avitene) was introduced in 1970. Microfibrillar applied collagen products 
come from the purification of bovine collagen, followed by microcristallisation. It is 
presented as a powder, and is more effective than gelatine based hemostasis, since it is able 
to activate the clotting cascade. 
3.4 Thrombin and fibrinogen (fibrin glue) 
Are the most recently appeared. 
Fibrin glues contain thrombin and fibrinogen: when combined, the fibrinogen is activated 
by thrombin and converted into fibrin monomere which form an adhesive glue at the tissues 
applied.  
The fibrin monomere interacts with the patient’s own factor VIII and calcium to convert the 
final product into a fibrin polymer that allows for platelets activation and aggregation with 
subsequent hemostasis. 
They are presented with a dual chamber syringe that allows for the combination of the 
thrombin and fibrinogen when the plunger is depressed. They also can be used in spray. 
Many commercial products are now on the market: Tisseel (Baxter), Evicel formerly called 
Crosseal (Johnson and Johnson)…Tisseel is now bovine free. 
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4. Classification of existing products 
4.1 Surgical local hemostatic agents with an aspecific effect on the clotting cascade 
Hemostatic agents with a natural origin 
Are medical devices of Class III, and may be extracted from animals (calf, ox, pig or horse) 
or plants (wood, cotton, alga, potatoe-starch) 
Mecanism of efficacy 
Collagen and gelatine induce the platelet aggregation leading to a clot when in contact with 
blood 
Oxidized cellulosis allows absorption of blood. Glycuronic acid diminishes the PH, induces 
vasoconstriction, and the creation of hematin film, and in vitro shows an bactericid effect. 
Alginates release the Ca++ ions , with a platelet activation followed by a fibrinoformation. 
Alga fibers reinforce the clot structure. 
Starch acts like a filter which concentrate the blood cells and the proteins such as thrombin, 
albumin and fibrinogen, with an hemostasis occurring in a few minutes. 
Different products 
Composition origin product presentation 
Collagen Calf Pangen compress 
 Ox Avitene  
 Pig Surgicol  
 Horse Antema (Biomet)  
  Tissufleece (Baxter)
Gentafleece (Baxter) 
Septocoll ( Biomet) + gentamycin 
Collatemp (Inocoll)
 
Gelatin Ox Floseal (Baxter) + Thrombin
Gelitaspon (Caps recherche) 
Gel 
powder, gel, pad 
  Pig Surgiflo Johnson & Johnson) gel 
  Spongostan (Johnson & Johnson)
Gelita (Pouret) 
Powder 
Plugs 
Oxidized 
cellulosis 
Wood Surgicel (Johnson&Johnson ) Compress 
 Cotton Gelitacel (Caps recherché)  
Alginates Laminaria 
Hyperborea 
Algosterile Compress 
Starch Potatoe Arista (Medafor) Powder 
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Hemostatic agents with a synthetic origin  
Their classification depends on their chemical category 
- Aldehyds associated with gelatine (GRF) or albumin (Bioglue –Gamida-) 
- Glycol polyethylens (Coseal –Baxter- and pleuraseal) 
- Cyanoacrylates (Glubran and Omnex) 
Mechanism of efficacy 
Their aim is the constitution of a film to obtain water tightness and prevent the risk of 
hemorrage 
They won’t be developed here their use being contraindicated in neurosurgery. 
4.2 Hemostatic agents with a specific effect on hemostasis cascade 
Concern four products containing all fibrinogen and thrombin, their difference is due to the 
different associated coagulating factors leading to product the last stage of the coagulation 
(Silver, Wang & AL 1995, Jackson 2001). Experimental studies have compared the properties 
and efficacy of the different fibrin sealants (Dickneite, Metzner & Al 2003) in correlation with 
their components. They emphasized the necessity of Factor XIII as the key of a good efficacy 
for clotting. All tested fibrin sealants performed well on individual parameters, but Beriplast 
(Aventis Behring) was the foremost fibrin sealant in consistently providing early hemostasis. 
These products are the Tissucol, the Beriplast, the Quixil and the Tachosyl. 
Each one contains other coagulation factors (Factor XIII, fibronectin,plasminogen), and an 
antifibrinolytic. 
The Quixil contains no substance from animal origin, but transnenamic acid and 
subsequently must never be in contact with nervous tissues.  
Tissucol (Baxter) 
- Can exist as a solution or a spray 
- *Powder and reconstitution solution I 
- Contains human components: fibrinogen (90mg/ml), Factor XIII(10UI/ml), 
fibronectin(5,5mg/ml), plasminogen0,08mg/ml), bovine aprotinin (3000 UIK/ml) 
- *Powder and reconstitution solution II 
- Contains human thrombin (500 UI/ml) 
- *The excipient of powder and reconstitution I 
- Contains glycin, human albumin, sodium nitrate, tyloxapol 
- *The excipient of powder and reconstitution solution IIContains Glycin, Sodium 
chlorure, reconstitution solution EPPI, Calcium chlorure 
- Must be kept in refrigerator, can be kept for 2 years 
- After reconstitution remains stable for 4 hours 
Beriplast (Nycomed) 
- Same presentation 
- *Powder and reconstitution solution I 
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- Contains human components: Fibrinogen (90mg/ml), Factor XIII( 60UI/ml), with 
bovine aprotinin (1000UIK/ml) 
- *Powder and reconstitution II 
- Contains human thrombin (500UI/ml) 
- *Powder and reconstitution solution  
- Contains human thrombin (500UI/ml) 
- *Powder and reconstitution solution I 
- Contains Isoleucin, Arginin, Sodium glutamate, human albumin, Sodium citrate, 
reconstitution EPPI, Sodium chlorure 
- Can be kept for one year at room temperature, and 2 in refrigerateur 
- Remains stable for 24 hours after preparation. 
Quixil (Johnson &Johnson) 
We don’t detail its composition for the previously related reason. 
Tachosil (Nycomed) 
Presents as compress 
- *The white side is covered with human fibrinogen( 5,5mg/cm2 
- * The yellow side with human thrombin (2UI/cm2 
- The excipients associate horse collagen, human albumin, Riboflavin, sodium chlorure, 
sodium citrate, L-Arginin. 
- Can be kept for three years at room temperature  
Autolog fibrin:Vivostat system (Vivolution) 
- Is a medical device whose the European autorisation has been given in 2000. 
- This automatized system can provide autolog from the patient blood in 23 minutes. 
- It associates a processor, a Kit preparation and a spray system. 
- It contains no animal component so it eliminates all risks of viral transmission 
- Nowadays, it is mainly used in cardiac and thoracic surgery, in vascular and abdominal 
surgery, but not in neurosurgery.  
5. Patches and pads  
Those non-invasive hemostatic closure devices as described by Hirsch, Reddy & Al 2003 are 
mainly used to obtain hemostasis of percutaneous arteriotomy sites of arterial catheterization. 
This type of patch comes from the studies confirming the hemostatic properties of a high-
molecular –weight polysaccharide the poly-N-acetyl-glucosamine (p-Glc-Nac).  
Its use is mostly in cardiac surgery and and in interventional radiology.  
5.1 Choice of the device and indications 
First we shall remind that some specialities are contra-indicated in neurosurgery: 
cyanoacrylates, Quixil, alginates. H2O2 must only be used out of the dura mater. 
The choice of the product and the strategy for local hemostasis are correlated with the type 
of neurosurgery, the sources of the bleeding, and the neurosurgeon practice, and the 
financial supplies. 
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No one must expect from local hemostatic products whatever their quality to be a substitute 
for the classical bipolar electrocoagulation hemostasis, and more widely for the respect of 
the tissues. 
5.1.1 Type of bleeding  
Arterial bleeding 
Bipolar coagulation must be used and gives a perfect adequacy to the needs if associated 
with irrigation. 
Bleeding from a venous sinus 
The suture remains the best mean when possible, possibly reinforced with a muscle or 
aponevrotic patch. If the bleeding is close to the vault, the suspension of the dura mater to 
the bone with interposition of a patch of muscle, oxidized cellulosis or both is the solution. 
Anterior cavernous sinus bleeding can be controlled by injection of fibrin glue with a good 
hemostasis. However of the series reported by Sekhar, Natarajan & Al 2007, of the 20 
patients who had an injection in the superior petrosal sinus, 2 experienced complications 
caused by occlusion of veins draining the brainstem. The 46 whose anterior cavernous sinus 
had been injected had no complications. 
Diffuse bleeding “cloth-bleeding” 
A global hemostasis disturbance must be searched. 
Local hemostatic agents are indicated, the most often oxidized cellulosis (surgical) will be 
applied, as well as tissucol (solution or spray). 
Bone bleeding 
Bone wax remains the most commonly used device, with a good efficacy. However, large 
amounts must be avoided for they will stay there for ever as a foreing body, and may be the 
cause of chronic infection, and a secondary removal. 
When skull base surgery is performed, surgical, muscle can be on the bleeding site. According 
to the concerned neurosugeons, the most effective product is the Floseal (powder). 
Dura mater water-proof 
Prevention of cerebro-spinal fluid (CSF) leaks must be done by the tight closure of the dura 
mater, reinforced if necessary by application of Surgicel. 
Large defects require a graft which can also be sutured, the suture of which may be 
reinforced in the same way. 
In large defects of the dura mater or on the skull base, most of the neurosurgeons will fill the 
defect with autolog fat tissue (easily indentified on post-operative CT-scan or MRI pictures) 
associated with glue (Tissucol or Bioglue). An external lumbar CSF derivation will be added 
in the most difficult cases. 
N-B: A local hemostatic agent will never by itself be sufficient to give a definitive water-
proof security. 
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5.2 Main uses in daily practical practice 
Skull and brain injuries 
The surgery of the skull base defects requires in most of the cases the filling of bone 
defects with tailed bone grafts, followed by the suture and/or grafting of the dura mater 
and as previously described the application of a local agent, Surgicel being the most 
widely used. 
Brain contusions require after excision of the necrotic tissues to apply some Surgicel if any 
small bleeding goes on, the best option being to obtain a very good hemostasis with nothing 
left in the remaining cavity. 
Opened cranio-cerebral wounds must be cleaned with a non-aggressive product, and H2O2 
is still indicated in such circumstances. 
Transphenoidal surgery 
Bleeding during pituitary surgery with a transphenoidal approach can lessen visibility, and 
this confined narrow route does not allow the use of electrocoagulation. The use of oxidized 
cellulose or glue is very useful. Ellgala, Maartens & Al 2002 have tested the use Floseal 
during 293 with a satisfying result. 
Endoscopic surgery 
The endoscopic treatment of CSF leaks of the anterior skull base whatever their a aetiology, 
includes the identification of the defect, the filling of the defect with a fragment of the 
medial turbinate fixed with bioglue followed by appliance of the rest of the pedicled 
turbinate below and oxidized cellulose (Surgicel) packing. 
Same procedures using muscle or turbinate may be used if a leak occurs during an 
hypophysis surgery procedure, Surgicel being commonly used to maintain the devices and 
/or to reinforce hemostasis. 
Some devices such as catheters are very useful in those deep tight fields. 
Spine and spinal cord surgery 
Vertebral plexus are better controlled with local hemostatic agents. Fibrin glue is effective 
when the more common appliance of Surgicel is not effective (Sekhar, Natarajan & Al 
2007) 
Spinal cord tumors must be approached through laminotomy, the lamina section being done 
with a craniotomy. After retraction of the posterior arch flap, the extradural hemostasis 
must be perfect sometimes difficult due to epidural veins. Bipolar coagulation of the veins 
will be completed by appliance of small fragments of Surgicel, and bone wax on bone 
section the opening of the spinal cord is done under magnification. Surgicel application will 
help for hemostasis, the coagulation use being as restricted as possible. 
After the tumour removal, no hemostatic agent should be left intradurally. The closing of 
the dura mater is seldom absolutely waterproof, and Surgicel and glue are commonly used 
to improve its quality (Lapierre 2009). 
In other intra-dural spinal surgery one must avoid to let in situ any agent. 
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Brain surgery 
From the extra-dural stage to the ending of the extradural hemostasis after the dura mater 
closure, local hemostatic agents have their place all along the procedure, to protect the brain, 
and to complete local hemostasis (Federspiel, Josephson &Al). In brain tumours, oxidized 
cellulose (surgical) is widely used, during the ablation of the tumour and at the end of the 
procedure to prevent and stop any bleeding in the remaining cavity whatever the type of 
tumor. One must be aware that it is still illegal to let products like Surgicel inside brain 
cavities, and inside the dura mater. Many physicians however will not take this in account 
considering the appliance of local agents on previously bleeding walls a better security for the 
patient. Tschan & Al 2010 have also evaluated the efficacy and safety of micropolysaccaride 
hemispheres (MPH) with no reported adverse effect. As soon as postoperative day 1, MPH 
were not detected anymore. There was no tumor mimicking enhancement. Many publications 
and everyone experience however report signal anomalies on post operative imagery 
mimicking residual tumour or early recurrence, or even an abcess, or a cotton pad when using 
Surgicel or gelatine sponge (Maurer, Ekholm & Al 1986)…This has led to some iterative 
unuseful surgery and even legacy. The histologic study only shows granuloma. 
In aneurisms surgery, before the development of interventional radiology, aneurisms who 
could not be clipped were wrapped with muscle and hemostatic agents, unsuccessfully. 
Nowadays, surgery of aneurisms only requires hemostatic agents during the procedure to 
protect the brain and stop the faint bleedins coming from the neighbouring. Appliance of 
some small Surgicel pieces to the aneurism neck and clip may help to maintain the clip 
parallel to the vessel direction when releasing the retractors. 
Spinal surgery 
Local hemostatic agents have many indications in spinal surgery of all types, especially to 
ensure the epidural veins hemostasis. 
They must not be left in contact with nerve roots intra or extradurally, due to the possibility 
of granuloma formation. Their presence is credited of the appearance of post-operative pain. 
In case of epidural spontaneous hematomas they are very useful particularly if they are due 
to anti-coagulant accidents. 
A randomized study performed in 127 patients by Renkens, Payner & Al 2001 comparing 
Floseal, microfibrillar collagen (Aviten) and fibrin glue showed the control of hemostasis in 
ten minutes for 97% of the cases with Floseal, and for 71% with the other agents. 
6. Listing of main complications 
Stroke  
Is only reported when using hydrogen peroxide (H2O2). Mut, Yemisci & al 2009 reported 
one case in a patient, after which they performed an experimental study on mice brains 
using 3% H2O2 solution. When H2O2 was applied on the cortex, a vasoconstrictive 
response of all arteries and arterioles of the treated zone was observed, and after 15 seconds 
of exposure to H2O2, multiple bubbles were observed within the lumen of all subpial 
arteries when pial layer had been destroyed, or not. 
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Histology revealed the production of peroxynitrite, and the diffusion of H2O2 through the 
superficial cortical layers. The addition of peroxide and H2O2 resulted in platelet 
aggregation and acute thrombus formation. The combination of NO and H2O2 is cytotoxic, 
and mediated by generated NO radicals. Among them, peroxinitrite is a potent and 
destructive oxdant, which may disrupt the blood-brain barrier. 
Those data confirm that H2O2 must only be used in the extra-dural space. 
Peripheral nerve impairment 
The potential effect of hemostatic agents of peripheral nerve function was suspected by 
clinical experience of postoperative local deficit or pain after the appliance of hemostatic 
agents in situ. 
Experimental studies heve been performed by Nagamatsu, Podratz & al 1996 and Alkan, 
Inat & al 2007. 
The first used oxicel (OC) (Deseret medical, Becton Dickinson and Company, Sandy, Utah) 
for studies in vitro and in vivo in rats. In vitro, neurite outgrowth of the dorsal root ganglion 
neuron was inhibited after 15 minutes exposure 
In vivo, the Ph was lowered in the subperineurium, and remained low for 2 hours. The 
acidity of the oxidised cellulose is involved in the development of experimental neuropathy 
by OC. The direct application of OC to peripheral nerves must be avoided. 
The second studied the effect of oxidized regenerated cellulose, gelatine sponge, bone wax 
and bovine collagen on the sciatic nerve of the rat, embedded in each substance. The 
compound action potential (CAP), and the nerve conduction velocity (NCV) were studied 
one hour and four weeks after the operation. In the bovine collagen and bone wax groups 
they were no statistically significant differences compared with initial control group.  
In the gelatine sponge group, CAP was increased statistically significantly 4 weeks after 
surgery. 
 In the oxidized regenerated cellulose, NCV was significantly reduced, and the CAP 
increased 1 hour after surgery. No significant difference was seen after 4 weeks, but partial 
necrosis and walking disturbances were seen on the operated legs after 1 to 3 weeks. 
Bovine collagen seems the most adapted for direct appliance to the nerves. 
Intra-spinal retained Surgicel can induce radiculopathy (Partheni, Kalogheropouplou & Al 
2006) and MRI studies could not exclude a post-operative hematoma, leading to reoperate 
the patient 
Granulomatous formations  
When left in the operative field, hemostatic agents may induce early or late tissue reactions 
and the formation of granulomas especially oxidized cellulose ( Voormolen, Ringers & Al 
1987) . Kaymaz, Tokgoz & al 2005, in an experimental study in the rabbit brain report the 
modifications due to the application of oxidized cellulose and gelatine sponge. They observe 
on MRI a perilesional oedema in both series, while histopathology a tissue-degeneration 
more marked with the gelatine sponge use 24 hours after operation. In a rat brain 
neurosurgical model (228 animals), Ereth, Schaff & Al 2008 studied Arista, Surgicel, Avitene, 
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Floseal or Kaolin (positive control) and showed the presence of residual material in all 
animals with Avitene, Surgicel and Floseal at day 14. Avitene and Floseal demonstrated a 
propensy for causing granuloma formation.  
Apel-Sarid, Cochrane &Al 2010 report a pediatric case series of 3 patients: the 3 cases had 
intra cerebral surgery (2 for tumors ablations, and one focal dysplasy treatment). The local 
hemostatic used agent was microfibrillar collagen haemostat (Avitene). The three had a 
second surgery for new or recurrent seizures, and MRI exploration suspected either a 
tumour recurrence or an abscess. Histologically, the mixed inflammatory infiltrate was 
typified by the presence of Avitene-centric necrotizing granulomas surrounded by a 
palisade of macrophages and often several eosinophils. 
So long, one must remain aware that the best behaviour is to remove any local hemostatic 
agent before closing the dura, if possible. 
Viral transmission 
With purified products, the risk of viral transmission has become very weak but is not 
totally missing, since all the products contain bovine components except for Vivostat. No 
recent report has been published yet. Virally inactivated human thrombin has replaced now 
bovine thrombin in most European products. (Buttusil 2003) 
Antibodies formation and immunologic concerns 
In the series of Renkens, Payner & Al 2001, at 6-8 weeks post operative evaluation of 
antibodies again bovine thrombin and bovine FactorVa demonstrated no stastical 
significance in the differences between treatment and control groups. 
There was no evidence of antibody-related coagulopathy in either group. However, 
immunology mediated coagulopathy associated with exposure to bovine thromin or to 
fibrin sealants containing this component is widely recognized. This component had to be 
replaced by human thrombin (Buttusil 2003). Bovine aprotinin (BA) may induce severe 
anaphylactic reactions, especially in patients previously treated with such products, 
suggesting that the use of a test dose should be proposed.  
Crosseal A containing traneximic acid (TA) eliminates this risk, but is contraindicated for 
neurosurgery. 
7. Financial point of view for hemostatic agents 
The most sophisticated they are, the most expansive. Anyway, the most daily used of all 
remain the oxidized cellulose, and the coast remains important. I should dare to add 
considering the glues that during the 15 years of my practice they did not exist. When they 
were available I have been using them for the ten following years.  
After some warning about security, I stopped. The results remain identical during these 
three consecutive periods. 
In developing countries, the price remains prohibitive, and in other countries, the local 
hemostatic agents are probably widely over-used. The indispensable devices remain 
electrocoagulation, Horsley wax, associated with a cautious and accurate surgery. The 
indication of local hemostatic agents must be evaluated in terms of rik-benefit for the 
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patient, and not considered as a comfort for the surgeon. Of course local hemostatic agents 
are useful in some cases, but must not considered as compulsory in the daily practice. 
8. Disclosure 
The authors report no conflict of interest concerning the materials ad devices described in 
this paper. 
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